The market size value per capita for hormones in dosage, excluding contraceptives and antibiotics, in France is forecasted to be stable at approximately $86.17 from 2024 to 2026. A slight decrease is expected, changing to $86.16 in 2027 and maintaining this level through 2028. As of 2023, the actual market value is consistent with these forecasted figures, indicating a period of equilibrium without significant growth or contraction. The compound annual growth rate over this five-year period is effectively zero, showcasing stagnation.
Future trends to watch include potential policy changes affecting healthcare funding, which could alter market dynamics. Additionally, technological advancements in pharmaceutical manufacturing and shifts in healthcare demand due to demographic changes might impact the market trajectory beyond 2028.
